New drug combo vs. chemo for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 70 years old.
- You have advanced triple-negative breast cancer that has gotten worse after at least one and up to four previous treatments, including a type of chemo called a taxane or anthracycline.
- You can swallow tablets.
- You are able to do daily activities with little or no help (ECOG 0-1).
- You have not taken certain drugs before, such as anti-angiogenic drugs (like Avastin) or eribulin, or certain immune therapies (like CTLA-4, Tim-3, LAG-3 blockers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
Hear when a new Breast Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.